Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | ELM-2: QoL and ORR outcomes of odronextamab treatment for R/R FL

Benoit Tessoulin • 11 Dec 2023
ASH 2023
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Odronextamab
ELM-2

Benoit Tessoulin, MD, Nantes University Hospital, Nantes, France, discusses the ELM-2 trial (NCT03888105), evaluating the efficacy of odronextamab, a bispecific antibody, in treating relapsed/refractory (R/R) follicular lymphoma (FL). The trial demonstrated an impressive overall response rate (ORR) of 80%, alongside favorable patient-reported quality of life (QoL) outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Gilead: Honoraria; Abbvie: Honoraria; Incyte: Honoraria; Kite: Honoraria.

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals